Details

Autor(en) / Beteiligte

• Samimi, M.
• Molet, L.
• Fleury, M.
• Laude, H.
• Carlotti, A.
• Gardair, C.
• Baudin, M.
• Gouguet, L.
• Maubec, E.
• Avenel-Audran, M.
• Esteve, E.
• Wierzbicka-Hainaut, E.
• Beneton, N.
• Aubin, F.
• Rozenberg, F.
• Dupin, N.
• Avril, M.F.
• Lorette, G.
• Guyetant, S.
• Coursaget, P.
• Touzé, A.

Titel

Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma

Ist Teil von

• British journal of dermatology (1951), 2016-04, Vol.174 (4), p.813-822

Ort / Verlag

England: Blackwell Publishing Ltd

Erscheinungsjahr

2016

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Summary Background Merkel cell polyomavirus (MCPyV) is the main aetiological agent of Merkel cell carcinoma (MCC). Serum antibodies against the major MCPyV capsid protein (VP1) are detected in the general population, whereas antibodies against MCPyV oncoproteins (T antigens) have been reported specifically in patients with MCC. Objectives The primary aim was to assess whether detection of serum antibodies against MCPyV proteins at baseline was associated with disease outcome in patients with MCC. The secondary aim was to establish whether evolution of these antibodies during follow‐up was associated with the course of the disease. Methods Serum T‐antigen and VP1 antibodies were assessed by enzyme‐linked immunosorbent assay using recombinant proteins in a cohort of 143 patients with MCC, including 84 patients with serum samples available at baseline. Results Low titres of VP1 antibodies at baseline (< 10 000) were significantly and independently associated with increased risk of recurrence [hazard ratio (HR) 2·71, 95% confidence interval (CI) 1·13–6·53, P = 0·026] and death (HR 3·74, 95% CI 1·53–9·18, P = 0·004), whereas T‐antigen antibodies were not found to be associated with outcome. VP1 antibodies did not differ between patients in remission and those with recurrence or progression during follow‐up. However, T‐antigen antibodies were more frequently detected in patients with recurrence or progression at 12 months (P = 0·020) and 24 months (P = 0·016) after diagnosis. Conclusions VP1 antibodies constitute a prognostic marker at baseline, whereas T‐antigen antibodies constitute a marker of disease recurrence or progression if detected > 12 months after diagnosis. What's already known about this topic? Antibodies against the Merkel cell polyomavirus major capsid VP1 protein are reported to be associated with recurrence in patients with Merkel cell carcinoma, but any association with mortality is unknown. Antibodies directed against T antigens are reported to be associated with disease progression, but their prognostic value is unclear. What does this study add? T‐antigen antibodies at baseline in patients with Merkel cell carcinoma were not associated with outcome. Antibodies against VP1 at baseline were associated with both recurrence and mortality. Linked Comment: Singh and Calonje. Br J Dermatol 2016; 174:715–716.